A Clinical Study of TQB2618 Injection Combined With Penpulimab Injection and Anlotinib Hydrochloride Capsules for First-line Treatment of Advanced Hepatocellular Carcinoma (HCC).
This is an open, single-arm, multi-center clinical study designed to evaluate the efficacy and safety of TQB2618 injection combined with penpulimab injection and Anlotinib Hydrochloride Capsules in patients with advanced HCC.
Advanced Hepatocellular Carcinoma
DRUG: Penpulimab injection|DRUG: TQB2618 injection|DRUG: Anlotinib Hydrochloride Capsules
Overall response rate (ORR), Percentage of subjects achieving complete response (CR) and partial response (PR)., Up to 2 years.
Overall Survival (OS), OS is defined as the time from the first time the subject received treatment to death due to any cause., Up to two and a half years.|Progress Free Survival (PFS), The time from the first administration of the drug to disease progression or death (whichever occurs first)., Up to 2 years.|Disease Control Rate (DCR), Percentage of subjects achieving CR and PR and stable disease (SD) is greater than or equal to 4-6 weeks., Up to 2 years.|Duration of Response (DOR), The time from the first assessment of the tumor's CR or PR to the disease's first progression or death from various causes., Up to 2 years.|Incidence of Anti-Drug antibody (ADA), The incidence of ADA after the administration of TQB2618., Before administration on the first day of the 1st, 2nd, 4th, and 8th cycles, 30 days and 90 days after the last administration. Each cycle is 21 days.|Incidence of neutralizing antibodies (Nab), The incidence of Nab after the administration of TQB2618., Before administration on the first day of the 1st, 2nd, 4th, and 8th cycles, 30 days and 90 days after the last administration. Each cycle is 21 days.|Incidence of adverse events (AEs), All adverse medical events that occur after the subject receives the investigational drug, evaluated according to the Common Terminology Criteria for Adverse Events Version 5.0 (CTCAE v5.0)., Baseline up to 2 years.|Severity of adverse events (AEs), All adverse medical events that occur after the subject receives the investigational drug, evaluated according to the Common Terminology Criteria for Adverse Events Version 5.0 (CTCAE v5.0)., Baseline up to 2 years.|Incidence of Serious adverse events (SAEs), It refers to adverse medical events such as death, life-threatening, permanent, or serious disability or loss of function, hospitalization or prolonged hospitalization, and congenital abnormalities or birth defects after the subject receives the experimental drug., Baseline up to 2 years.
This is an open, single-arm, multi-center clinical study designed to evaluate the efficacy and safety of TQB2618 injection combined with penpulimab injection and Anlotinib Hydrochloride Capsules in patients with advanced HCC.